2nd Generation Amylinomimetic

This second generation amylin analog, optimized for treatment of obesity, is being studied as a stand-alone therapy and also in combination with other hormones. Its potential for once weekly dosing will be explored in 2008.

Integrated Neurohormonal Therapy for Obesity (INTO) Program

Amylin is leveraging its science to continually advance diabetes care and to deliver new treatments for obesity and other diseases. A potentially transformational therapy in development is a unique combination of pramlintide and metreleptin, an output of Amylin's Integrated Neurohormonal Therapy for Obesity (INTO) program. The program is designed to harness the naturally occurring power of peptide and protein hormones and apply them in combination for improved patient outcomes in the struggle for weight loss.